基础医学与临床2013，Vol.33Issue(3)：382-386,5.
Crizotinib在ALK基因阳性非小细胞肺癌中的临床研究进展
Clinical research progress of crizotinib in ALK-positive non-small cell lung cancer patients
唐敏 1武晓楠 1程刚1
作者信息
- 1. 卫生部北京医院肿瘤内科,北京100730
- 折叠
摘要
Abstract
Crizotinib is a selective ATP-competitive inhibitor of anaplastic lymphoma kinase (ALK), hepatocyte growth factor receptor(c-Met/HGFR) tyrosine kinases and their oncogenic variants. In PROFILE 1001 and PROFILE 1005 clinical trials, the response rate of crizotinib is 50% ~ 60% for non-small cell lung cancer(NSCLC) patients with ALK rearrangement. Most of the adverse events are grade 1 ~2. Vysis ALK breakapart FISH probe kit is a standard diagnostic test to detect ALK-rearrangement. ALK-rearrangement is more often seen in never/light smokers with lung adenocarcinomas. The mechanism of crizotinib resistance is complicated.关键词
克唑替尼/间变性淋巴瘤激酶基因重排/非小细胞肺癌Key words
crizotinib, anaplastic lymphoma kinase gene rearrangement, non-small cell lung cancer分类
医药卫生引用本文复制引用
唐敏,武晓楠,程刚..Crizotinib在ALK基因阳性非小细胞肺癌中的临床研究进展[J].基础医学与临床,2013,33(3):382-386,5.
